Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFrEF Patients With Type 2 Diabetes: Effect on Left Ventricular Remodeling
ChiCTR2300072707Phase 4Completed
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) comparing dapagliflozin group with placebo group (2 arms). Primary endpoints: Left ventricular ejection fraction, Left ventricular end-diastolic volume and 3 more. Started Sep 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300072707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072707.